Activation of the cellular immune system is discussed to be partly responsible in the neurodegenerative process of Parkinson's disease. We determined concentrations of neopterin, of cytokine interleukin-6, and of soluble cytokine receptors sIL-2Rα, sTNF-R75α in plasma and cerebrospinal fluid in controls and patients with vascular parkinsonism and idiopathic Parkinson's disease diagnosed according to published clinical diagnostic criteria, to examine if the cellular immune system is activated locally or peripherally or both. Our results show no activation in idiopathic Parkinson's disease and controls, but a significant increased activation in vascular parkinsonism, where concomitant signs of cerebrovascular disease are present.
Introduction
Idiopathic Parkinson's disease (IPD) is one of the most common neurodegenerative diseases in the elderly. Parkinson's disease is characterized by a loss of nigrostriatal dopaminergic neurons -on the one hand associated with a significant glial reaction, especially in the substantia nigra pars compacta (1), leading to a mild increase in the number of astrocytes and in the immunoreactivity for glial fibrillary acid protein, -and on the other hand leading to a diminished presence of the enzyme tyrosine hydroxylase, the key enzyme in dopamine biosynthesis (2) . Different hypotheses were proposed for the aetiology of IPD, but recently there was some discussion whether cell-mediated immune activation may play a role in this neurodegenerative process (3, 4, 5, 6, 7, 8) . As some interleukins are synthesized by activated glial cells and the very controversially findings about immune activation in IPD patients led us to investigate whether neopterin, proinflammatory cytokine interleukin-6 (IL-6), soluble cytokine receptors sTNF-R75α or IL-2sRα are increased locally (cerebrospinal fluid, CSF) or peripherally (plasma) or both, in patients with IPD in comparison to patients with vascular parkinsonism (VP) and control subjects.
Materials and Methods
Twenty-two patients of both sexes, submitted because of Parkinsonian symptoms, and 7 nonParkinsonian controls were investigated. Inclusion criteria for patients were a diagnosis of either IPD according to the Queen Square Brain Bank criteria (9) , or a diagnosis of VP according to published diagnostic criteria (10) . Patients who were admitted to our hospital because of parkinsonian symptoms and fulfilled the outlined criteria were asked to participate in this study. On the basis of a thourough clinical investigation including detailed history, MR imaging, SPECT imaging, videomonitoring and neuropsychiatric investigation, the patients were subdivided into two groups -IPD and VP (see Table 1 ). Sex matched controls were investigated because of suspected central nervous system diseases but were finally diagnosed as suffering from myelopathy, neuropathy or headache. The mean age of the control group was not significantly different compared to the IPD, but was significantly lower compared to the VP group (p<0.001). Also a significant age difference was found between the IPD and VP group (p=0,012). This age difference between the investigated groups must be taken into account especially for discussion of neopterin concentrations in plasma and CSF, where neopterin increases with age.
The evidence of an acute or chronic inflammatory process was excluded by routine blood studies as well as routine CSF parameters including cytology, albumin, isoelectric focusing and viral titer. IPD patients had neither an acute ischaemic insult nor a previous vascular damage. A vasculitis was excluded in all patients and controls.
At the time of investigation all patients were on dopaminergic therapy.
Study was performed according to the Helsinki declaration, all participants signed an informed consent prior to study enrolment.
Between 8 a.m. and 10 a.m. blood samples were collected into cooled EDTA coated vials, centrifuged for 15 minutes at 3000 U, the plasma was taken off and subsequently frozen at -70°C until assay. CSF samples were taken by lumbar puncture in sitting position. CSF aliquots were also stored at -70°C until assay.
Neopterin concentrations in plasma and CSF were determined using an enzyme immunoassay (ELISA) (BRAHMS AG, Hennigsdorf, Germany), IL-6 by an immunoassay (R&D Systems, Inc., Minneapolis, MN, USA), and IL-2sRα and sTNF-R75α were estimated using high sensitivity enzyme-linked immunosorbent assays from R&D. In these two cases the determination of the soluble receptors is much more efficient than measurement of corresponding cytokine concentrations, because of the short biological half time and adsorption on the cell surface of the cytokines.
T-test was employed to identify significant differences of plasma and CSF analytes distributions. Table 2 shows the detailed results in IPD, VP and control patients. In IPD the mean values of neopterin observed in CSF and plasma were not different from those obtained in controls. However, raised but not significantly increased concentrations were seen in patients with VP in plasma compared to controls, but significantly increased compared to IPD (p = 0.009). Also significantly increased neopterin concentrations were found in CSF of VP compared to controls (p = 0.001) and compared to IPD (p = 0.009). It is well known that plasma neopterin concentrations increase with age (11). Though our VP patients are significantly older compared to the other groups, the highly increased neopterin levels in plasma might not only derive from this fact. Several authors mentioned that neopterin concentrations in CSF and peripheral circulation are not correlated (12) . Therefore it may be speculated that in the VP group the cellular immunity in the central nervous system was activated much more than in the periphery, leading to significant increase of neopterin in CSF. Degenerative and vascular processes (multicerebral infarcts) are described to be able to start immune reactions by activating macrophages leading to increased neopterin concentrations in plasma (13) . The amounts of neopterin produced by activated monocytes/macrophages correlate with their capacity to release reactive oxygen species (ROS) (14) . Neopterin concentrations in body fluids can therefore be regarded as an indirect estimate of the degree of oxidative stress emerging during cell mediated immune response. Widner and coworkers (15) presumed that immunopathogenesis appears to be confined to the brain, because only a subgroup of IPD patients suffering from Parkinson's disease presented With regard to neopterin our results suggest that in IPD the cellular immune system was not activated in contrast to patients with VP. We believe that cerebrovascular events are responsible for increased neopterin levels, especially in CSF, of these patients.
Results
TNF-α is predominately produced by microglia and astrocytes. As in substantia nigra density of microglial cells is remarkably higher than in other brain areas and the finding that substantia nigra neurons are more susceptible to activated microglial-mediated injury (19), Vila and coworkers (20) suggested that gliosis may play an especially meaningful role in PD, because glial-derived cytokines may also act directly on dopaminergic neurons by binding cell surface cytokine receptors e.g. TNF-α receptor. Hunot et al. (21) showed the expression of CD23 receptors on glial cells and astroglia in IPD patients, caused by TNF. After binding of specific antibodies on CD23, cytokineinducible nitric oxide synthase (iNOS) is activated leading to release of NO. The distribution of the CD23 positive cells in the substantia nigra of IPD patients was variable but interestingly the highest cell concentrations were found in the surrounding area of blood vessels. This could be the basis of our observation, namely that sTNF-R75α, which is a truncated form of the TNF-R75 (Type a, molecular weight 75 kDa) was significantly increased only in patients with VP (in plasma p <0.05; in CSF p = 0.011 compared to controls; and p <0.05 in plasma and p = 0.014 in CSF compared to IPD) and not in IPD patients, what once more shows that activation of the cellular immune system may be due to vascular events.
IL-6 is a pro-inflammatory cytokine which usually is increased in traumata and ischaemic processes. TNF Table 2 . Neopterin, interleukin-6 (IL-6), soluble 75kD tumor necrosis factor receptor-α (sTNF-R75α) and interleukin 2 soluble receptor-α (IL-2sRα) concentrations in plasma and CSF of controls, patients with idiopathic Parkinson's disease (IPD) and vascular parkinsonism (VP) ( is able to induce the secretion of IL-6. Concentrations of IL-6 in our study showed similar results as neopterin and sTNF-R75α. All patient groups had increased levels in serum as well in CSF compared to controls, the highest levels were again found in patients with VP. But by reason of high standard deviations, significance could be achieved only in plasma of VP compared to controls (p <0.05). IL-2sRα concentrations were decreased in plasma of all patients, in IPD significantly compared to controls (p = 0.012). The same significant decrease of IL2sRa could be observed in CSF of IPD (p = 0.011) and of VP (p = 0.009) compared to controls. It should be mentioned that only IL-2sRα concentrations were so drastically diminished in plasma and even stronger in CSF of all patients compared to controls whereas all other investigated markers were increased. Kluter et al. (22) found decreased IL-2 concentrations in peripheral blood mononuclear cells of IPD patients. IL-2 is produced by activated helper T-cells and is required for appropriate lymphocyte function and proliferation. The possible explanation for the deficit of IL-2 might be a lack of co-stimulatory signals, inhibition by suppressor cells, or variations in the IL-2 producing T-cell population. Namely, in humans two types of T-lymphocytes can be found -the naive and memory cells (23) . According to Sanders the memory cells produce less IL-2 as the naive T-cells. An increased number of memory cells in comparison to naive T-cells could be the explanation for the decreased IL-2 concentrations.
No correlations were found within the three groups between neopterin concentrations in plasma and CSF (Table 3) , confirming the results of Millner et al. (12) who could differentiate between central nervous system and peripheral infections in children by determining neopterin concentrations in serum and CSF. The three other investigated immune parameters (IL-6, sTNF-R75α, IL-2sRα) showed a high correlation between plasma and CSF in the IPD group, but in the VP group a high correlation only was found between plasma and CSF IL-6 concentrations (Table 3) .
Our results allow the conclusion that mechanisms of cytokine expression are dependent on the aetiology of Parkinson syndromes. The cell-mediated immune system is not activated in IPD, when results are compared with controls. Evidence of immune activation is found in VP in which parkinsonian symptoms are due to cerebrovascular damage. Further studies with an increased number of controls, IPD patients and age-matched VP patients are planed for confirming these results and for facilitating the differentiation between IPD and VP.
